· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
December 20, 2005
Subject: An association between PrAvandia® and PrAvandamet® and vision problems in diabetics
Mississauga, Ontario - Avandia® (rosiglitazone maleate) tablets and Avandamet® (rosiglitazone maleate/metformin hydrochloride) tablets are medications authorized for use in Canada to control blood sugar levels in diabetic patients whose blood sugar levels have not been controlled by diet, exercise or other medications. GlaxoSmithKline Inc. (GSK), after discussions with Health Canada, wishes to provide Canadians with important new safety information regarding rare reports of a specific vision problem called macular edema occurring in diabetic patients who were taking Avandia or Avandamet.
Macular edema is a swelling of the retina due to fluid at the back of the eye and may be more likely to occur in people with diabetic retinopathy (a disease of the retina caused by diabetes), high blood pressure, and/or poor control of their blood sugar levels.
Advice to patients using Avandia or Avandamet:
GSK has sent a letter to Canadian health-care professionals informing them of this new safety information. You may view this letter on the Canadian website of GlaxoSmithKline or on the website of Health Canada. GSK is working with Health Canada to revise the Canadian prescribing information for Avandia and Avandamet. If patients have questions regarding their current prescription, they are asked to contact their doctor or pharmacist. Health Canada will review this new safety information for Avandia and Avandamet and will do so for other similar drugs used for the treatment of diabetes.
Managing marketed health product-related adverse reactions depends on health-care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving Avandia or Avandamet should be reported to GlaxoSmithKline Inc. or Health Canada at the following addresses:
GlaxoSmithKline Inc.
7333 Mississauga Road North
Mississauga, Ontario
L5N 6L4
Telephone: 1 800 387-7374
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health CanadaAddress Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
Avandia® and Avandamet® are registered trademarks, used under license by GlaxoSmithKline.
For media inquiries, please contact Alison Steeves, (905) 819-3363.